Skip to main content
. Author manuscript; available in PMC: 2015 Jul 15.
Published in final edited form as: Oncogene. 2014 Jan 27;34(3):373–383. doi: 10.1038/onc.2013.562

Figure 1. Elafin increases ovarian cancer cell proliferation.

Figure 1

A. Kaplan Meier analysis for Overall Survival (OS) in ovarian cancer (OC) patients according to the expression of PI3 probe 41469_at (n=1058). B. OS in OC patients according to the expression of PI3 probe 203691_at (n=1058). Log-rank test. Median value as cut-off. C. Relative PI3 mRNA expression by quantitative RT-PCR among 11 OC cell lines. D. Effect of adding 300 nM of recombinant Elafin (rElafin) on proliferation of OC cell lines Hey-A8 and OVCAR8. E. Proliferation of Hey-A8 and OVCAR8 transfected with pcDNA3.0 vector encoding Elafin (Ela) compared to cell lines transfected with empty vector (Ctr). F. Scratch test on OVCAR8 cells overexpressing Elafin (Ela), control (Ctr) and non-transfected (NTC) line. Cell growth into the scratch is plotted in the graph as mm growth over time. The black bar represents 1 mm. G. Effect of mutations in the serine proteinase domains of Elafin, M85G and M85K, on cellular proliferation rates when compared to rElafin and vector coding for non mutant Elafin. Proliferation was measured using the Celltiter Glo assay in D, E and G.